Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.5K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
Proteomics01:33

Proteomics

10.0K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
10.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring differences in protein cargo of extracellular vesicles from ME/CFS patient plasma compared to healthy controls.

Biochemistry and biophysics reports·2026
Same author

Lipopolysaccharides Drive Proinflammatory Extracellular Vesicle Secretion in Coronary Artery Endothelial Cells via Noncanonical Inflammasome Activation.

Cellular and molecular life sciences : CMLS·2026
Same author

Proteomic evaluation and comparison of native and decellularized human saphenous vein extracellular matrices.

Frontiers in bioengineering and biotechnology·2026
Same author

Biallelic SUPT4H1 variants cause a multisystem neurodevelopmental disorder associated with disrupted transcription.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Proteome profiling of cerebrospinal fluid-derived extracellular vesicles reveals potential biomarkers for drug-resistant epilepsy.

Clinical proteomics·2025
Same author

Vacuolar-type H<sup>+</sup>-ATPase-mediated extra-organellar buffering resolves mitochondrial dysfunction.

Nature communications·2025

Related Experiment Video

Updated: Mar 6, 2026

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

4.1K

Transcriptomic and proteomic insights into progressive myoclonus epilepsy type 1.

Alina Malyutina1,2, Carina Lund1,3, Saara Tegelberg1,3

  • 1Folkhälsan Research Center, 00290 Helsinki, Finland.

Disease Models & Mechanisms
|March 5, 2026
PubMed
Summary
This summary is machine-generated.

Progressive myoclonus epilepsy (EPM1) research reveals cystatin B deficiency impacts brain immunity, energy metabolism, and lysosomal function. These findings offer potential therapeutic targets for this rare neurodegenerative disease.

Keywords:
Cstb−/− mouseBrainCystatin BEPM1ProteomicsTranscriptomics

More Related Videos

Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy
11:54

Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy

Published on: January 29, 2018

27.2K
Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

6.3K

Related Experiment Videos

Last Updated: Mar 6, 2026

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

4.1K
Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy
11:54

Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy

Published on: January 29, 2018

27.2K
Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

6.3K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Progressive myoclonus epilepsy type 1 (EPM1) is a rare neurodegenerative disorder.
  • It results from partial loss of function of cystatin B (CSTB), a neuroprotective protein.
  • Current treatments for EPM1 symptoms are lacking.

Purpose of the Study:

  • To investigate the molecular consequences of CSTB loss in the brain.
  • To identify potential therapeutic targets and biomarkers for EPM1.

Main Methods:

  • Comparative transcriptome and proteome analysis in CSTB-deficient (Cstb-/-) mouse brain regions (cerebellum, cerebral cortex, hippocampus).
  • Analysis focused on disease progression stages.

Main Results:

  • Upregulation of immune response genes across all analyzed brain regions.
  • Downregulation of oxidative phosphorylation and differential expression of mitochondrial genes, particularly in the cerebellum, indicating impaired energy metabolism.
  • Upregulation of lysosomal function genes alongside downregulation of genes for lysosomal acidification, suggesting lysosomal dysfunction.
  • Identification of clusterin, apolipoprotein E, peroxiredoxin 6, cathepsin D, and aldolase C as potential progression biomarkers.

Conclusions:

  • CSTB deficiency profoundly affects immune response, energy metabolism, and lysosomal function in the brain.
  • These pathways represent promising therapeutic targets for EPM1.
  • Identified proteins may serve as biomarkers for disease progression.